Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics


Nymox Pharmaceutical Corporation (NYMX): $1.52

-0.04 (-2.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NYMX POWR Grades


  • NYMX scores best on the Sentiment dimension, with a Sentiment rank ahead of 62.66% of US stocks.
  • NYMX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • NYMX ranks lowest in Value; there it ranks in the 9th percentile.

NYMX Stock Summary

  • With a price/sales ratio of 25,103.49, Nymox Pharmaceutical Corp has a higher such ratio than 99.91% of stocks in our set.
  • With a year-over-year growth in debt of 189.8%, Nymox Pharmaceutical Corp's debt growth rate surpasses 94.58% of about US stocks.
  • Revenue growth over the past 12 months for Nymox Pharmaceutical Corp comes in at -97.77%, a number that bests only 0.93% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Nymox Pharmaceutical Corp, a group of peers worth examining would be INMB, OCGN, BLU, CALT, and CYAD.
  • NYMX's SEC filings can be seen here. And to visit Nymox Pharmaceutical Corp's official web site, go to www.nymox.com.

NYMX Stock Price Chart Interactive Chart >

Price chart for NYMX

NYMX Price/Volume Stats

Current price $1.52 52-week high $4.23
Prev. close $1.55 52-week low $1.42
Day low $1.51 Volume 160,104
Day high $1.54 Avg. volume 284,929
50-day MA $1.85 Dividend yield N/A
200-day MA $2.28 Market Cap 124.81M

Nymox Pharmaceutical Corporation (NYMX) Company Bio


Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.


NYMX Latest News Stream


Event/Time News Detail
Loading, please wait...

NYMX Latest Social Stream


Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

InvestorPlace is starting the day off right by checking out the biggest pre-market stock movers, including the winners and losers.

William White on InvestorPlace | May 11, 2021

Nymox Announces Date for Fexapotide Filing

HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021. CEO Dr. Paul Averback said, "The Company will file on or before September 15. We hope but cannot be certain that the date may be before September. Company management will communicate updates where appropriate." About Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company’s lead dru...

Yahoo | May 6, 2021

Nymox Announces $8,000,000 Private Placement

HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.50 per share, will be immediately exercisable and will expire five years from the date of issuance. The Company expects to use the net proceeds from the private placement for working capital and other general corporate purposes. The private placement is expected to...

Yahoo | April 28, 2021

Do Insiders Own Lots Of Shares In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)?

The big shareholder groups in Nymox Pharmaceutical Corporation ( NASDAQ:NYMX ) have power over the company. Generally...

Yahoo | April 28, 2021

What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition

Every investor in Nymox Pharmaceutical Corporation (NASDAQ:NYMX) should be aware of the most powerful shareholder...

Yahoo | November 3, 2020

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo -11.63%
3-mo -41.09%
6-mo -46.29%
1-year -51.59%
3-year -54.63%
5-year -35.86%
YTD -38.71%
2020 12.73%
2019 67.94%
2018 -60.30%
2017 23.60%
2016 -18.60%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8734 seconds.